News

Public · Published

Guggenheim maintains Regeneron Pharmaceuticals at Buy, raises price target to $1100 from $1030

Guggenheim kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1100 from $1030, a 6.8% increase. The new target implies 18.5% upside from the October 30 closing price of $927.89.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1100 from $1030, a 6.8% increase. The new target implies 18.5% upside from the October 30 closing price of $927.89.

Confirmed

Global impact / market context

A higher price target signals that Guggenheim sees more potential value in Regeneron shares, but it is an analyst estimate, not a guaranteed return. If investors act on the more favorable view, demand for the shares could rise; the article gives no evidence of an actual market reaction.

Analyst inference

Recent analyst views are mixed: the five listed targets range from $875 to $1175, while Guggenheim’s new $1100 target sits within that spread. This shows that analysts do not share one valuation view; the article provides no company operating results or explanation for the differing targets.

Analyst inference

What to watch

  1. Compare future analyst ratings and price targets with Guggenheim’s $1100 estimate to see whether professional views converge or continue to differ. Analyst inference
  2. Check whether Regeneron reports business results or guidance that explains a change in expected value; no such operating details are included here. Analyst inference
  3. The supplied article lists targets of $875 to $1175 across five recent notes and reports Guggenheim’s Buy rating and revised target. Confirmed

Evidence

  • Original source link unavailable